Safety and efficacy of vigabatrin and carbamazepine in ne wly diagnosed epilepsy: a multicentre randomised double-blind study
- 3 July 1999
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 354 (9172), 13-19
- https://doi.org/10.1016/s0140-6736(98)10531-7
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- New antiepileptic drugs: a systematic review of their efficacy and tolerabilityBMJ, 1996
- Human brain GABA levels rise after initiation of vigabatrin therapy but fail to rise further with increasing doseNeurology, 1996
- MRI monitoring of vigabatrin‐induced intramyelinic edema in dogsNeurology, 1994
- Neuropathology of vigabatrin.British Journal of Clinical Pharmacology, 1989
- Double-blind Study of Vigabatrin in the Treatment of Drug-Resistant EpilepsyArchives of Neurology, 1987
- Double‐Blind, Placebo‐Controlled Study of Vigabatrin (Gamma‐Vinyl GABA) in Drug‐Resistant EpilepsyEpilepsia, 1986
- γ‐Vinyl GABA: A double‐blind placebo‐controlled trial in partial epilepsyAnnals of Neurology, 1985
- DOUBLE-BLIND STUDY OF γ-VINYL GABA IN PATIENTS WITH REFRACTORY EPILEPSYThe Lancet, 1984
- Increased gamma-aminobutyric acid (GABA), homocarnosine and β-alanine in cerebrospinal fluid of patients treated with γ-vinyl GABA (4-amino-hex-5-enoic acid)Life Sciences, 1981
- γ‐VINYL GABA (4‐amino‐hex‐5‐enoic acid), A NEW SELECTIVE IRREVERSIBLE INHIBITOR OF GABA‐T: EFFECTS ON BRAIN GABA METABOLISM IN MICE1Journal of Neurochemistry, 1977